Search

Adjuvant intravitreal dexamethasone implant for persistent CME

In this retrospective, cross-sectional study the authors investigate the efficiency of intravitreal dexamethasone implants (0.7mg) for cystoid macular oedema (CME) persisting, despite immunomodulatory treatment in patients with Behcets’ disease (BD). Twenty-seven eyes of 20 patients (12 males and eight females)...

Long-term outcomes of intravitreal ranibizumab for neovascular AMD

This is a single centre prospective study for the long-term, whole population ‘real-world’ clinical outcomes of ranibizumab therapy in treatment-naïve patients for neovascular age-related macular degeneration (AMD). This study recorded: demographics, Early Treatment Diabetic Retinopathy Study visual acuity (ETDRS VA)...

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...

Laser photocoagulation vs. intravitreal (IVT) aflibercept for ROP

The efficacy, recurrence rate and requirement for additional treatment were compared between laser photocoagulation and IVT of 1mg/0.025ml aflibercept in the treatment of retinopathy of prematurity (ROP). The study included 27 babies (51 eyes) who completed a follow-up period after...

Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO

This paper is an analysis of data extracted from 13 eligible studies in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), collected from systematic literature search of MEDLINE, Embase, and Cochrane...

Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery

This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...

Should intravitreal steroids be used in the initial treatment of post-op endophthalmitis?

Endophthalmitis following cataract surgery is one of the most feared complications, and can have significant impact on the visual outcomes of patients. The role of steroids in the management of endopthalmitis is controversial. The aim of this paper was to...

Short-term outcome after intravitreal ranibizumab injections for ROP

This is an interventional case series study of three premature babies (six eyes) with high risk prethreshold or threshold retinopathy of prematurity (ROP) with plus disease that received intravitreal ranibizumab injections for ROP. All infants received intravitreal ranibizumab injections of...

Do bilateral same day intravitreal injections increase the risk of endophthalmitis?

This large retrospective cohort study reviewed all patients who had bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections between April 2012 and August 2017. There were 101,932 procedures performed in 5890 patients. The two most common indications for injections were...

Incidence and outcomes of endophthalmitis with in-house compounded intravitreal bevacizumab injections

This multicentre study examining a five-year period from 2014 to 2018 evaluated the incidence rate and outcomes of endophthalmitis after intravitreal injection of in-house compounded bevacizumab. In-house compounded syringes were prepared in compounding pharmacy using sterile standard operating guidelines. All...

OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)

Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...